Skip to main content
NCBI home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1983 Dec 3;287(6406):1654–1656. doi: 10.1136/bmj.287.6406.1654

Amiodarone: the experience of the past decade.

W J McKenna, E Rowland, D M Krikler
PMCID: PMC1550155  PMID: 6416537

Full text

PDF
1654

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brochier M., Fauchier J. P. Torsades de pointe et rentrées provoquées par les antiarythmiques. Arch Mal Coeur Vaiss. 1978 Apr;71(4):477–488. [PubMed] [Google Scholar]
  2. Burger A., Dinichert D., Nicod P., Jenny M., Lemarchand-Béraud T., Vallotton M. B. Effect of amiodarone on serum triiodothyronine, reverse triiodothyronine, thyroxin, and thyrotropin. A drug influencing peripheral metabolism of thyroid hormones. J Clin Invest. 1976 Aug;58(2):255–259. doi: 10.1172/JCI108466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chalmers R. J., Muston H. L., Srinivas V., Bennett D. H. High incidence of amiodarone-induced photosensitivity in North-west England. Br Med J (Clin Res Ed) 1982 Jul 31;285(6338):341–341. doi: 10.1136/bmj.285.6338.341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. D'Amico D. J., Kenyon K. R., Ruskin J. N. Amiodarone keratopathy: drug-induced lipid storage disease. Arch Ophthalmol. 1981 Feb;99(2):257–261. doi: 10.1001/archopht.1981.03930010259007. [DOI] [PubMed] [Google Scholar]
  5. Dudognon P., Hauw J. J., de Baecque C., Derrida J. P., Escourolle R., Nick E. J. Neuropathie au chlorhydrate d'amiodarone. Etude clinique et histopathologique d'une nouvelle lipidose médicamenteuse. Rev Neurol (Paris) 1979 Jul-Aug;135(6-7):527–540. [PubMed] [Google Scholar]
  6. Fogoros R. N., Anderson K. P., Winkle R. A., Swerdlow C. D., Mason J. W. Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias. Circulation. 1983 Jul;68(1):88–94. doi: 10.1161/01.cir.68.1.88. [DOI] [PubMed] [Google Scholar]
  7. Haffajee C. I., Love J. C., Canada A. T., Lesko L. J., Asdourian G., Alpert J. S. Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias. Circulation. 1983 Jun;67(6):1347–1355. doi: 10.1161/01.cir.67.6.1347. [DOI] [PubMed] [Google Scholar]
  8. Hamer A., Peter T., Mandel W. J., Scheinman M. M., Weiss D. The potentiation of warfarin anticoagulation by amiodarone. Circulation. 1982 May;65(5):1025–1029. doi: 10.1161/01.cir.65.5.1025. [DOI] [PubMed] [Google Scholar]
  9. Harris L., Hind C. R., McKenna W. J., Savage C., Krikler S. J., Storey G. C., Holt D. W. Renal elimination of amiodarone and its desethyl metabolite. Postgrad Med J. 1983 Jul;59(693):440–442. doi: 10.1136/pgmj.59.693.440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Harris L., McKenna W. J., Rowland E., Holt D. W., Storey G. C., Krikler D. M. Side effects of long-term amiodarone therapy. Circulation. 1983 Jan;67(1):45–51. doi: 10.1161/01.cir.67.1.45. [DOI] [PubMed] [Google Scholar]
  11. Harris L., McKenna W. J., Rowland E., Krikler D. M. Side effects and possible contraindications of amiodarone use. Am Heart J. 1983 Oct;106(4 Pt 2):916–923. doi: 10.1016/0002-8703(83)90016-9. [DOI] [PubMed] [Google Scholar]
  12. Heger J. J., Prystowsky E. N., Jackman W. M., Naccarelli G. V., Warfel K. A., Rinkenberger R. L., Zipes D. P. Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med. 1981 Sep 3;305(10):539–545. doi: 10.1056/NEJM198109033051002. [DOI] [PubMed] [Google Scholar]
  13. Holt D. W., Tucker G. T., Jackson P. R., Storey G. C. Amiodarone pharmacokinetics. Am Heart J. 1983 Oct;106(4 Pt 2):840–847. doi: 10.1016/0002-8703(83)90006-6. [DOI] [PubMed] [Google Scholar]
  14. Ingram D. V., Jaggarao N. S., Chamberlain D. A. Ocular changes resulting from therapy with amiodarone. Br J Ophthalmol. 1982 Oct;66(10):676–679. doi: 10.1136/bjo.66.10.676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jaggarao N. S., Sheldon J., Grundy E. N., Vincent R., Chamberlain D. A. The effects of amiodarone on thyroid function. Postgrad Med J. 1982 Nov;58(685):693–696. doi: 10.1136/pgmj.58.685.693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Marchlinski F. E., Gansler T. S., Waxman H. L., Josephson M. E. Amiodarone pulmonary toxicity. Ann Intern Med. 1982 Dec;97(6):839–845. doi: 10.7326/0003-4819-97-6-839. [DOI] [PubMed] [Google Scholar]
  17. Marcus F. I., Fontaine G. H., Frank R., Grosgogeat Y. Clinical pharmacology and therapeutic applications of the antiarrhythmic agent amiodarone. Am Heart J. 1981 Apr;101(4):480–493. doi: 10.1016/0002-8703(81)90140-x. [DOI] [PubMed] [Google Scholar]
  18. McGovern B., Garan H., Kelly E., Ruskin J. N. Adverse reactions during treatment with amiodarone hydrochloride. Br Med J (Clin Res Ed) 1983 Jul 16;287(6386):175–180. doi: 10.1136/bmj.287.6386.175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. McKenna W. J., Harris L., Perez G., Krikler D. M., Oakley C., Goodwin J. F. Arrhythmia in hypertrophic cardiomyopathy. II: Comparison of amiodarone and verapamil in treatment. Br Heart J. 1981 Aug;46(2):173–178. doi: 10.1136/hrt.46.2.173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. McKenna W. J., Harris L., Rowland E., Whitelaw A., Storey G., Holt D. Amiodarone therapy during pregnancy. Am J Cardiol. 1983 Apr;51(7):1231–1233. doi: 10.1016/0002-9149(83)90377-6. [DOI] [PubMed] [Google Scholar]
  21. Moysey J. O., Jaggarao N. S., Grundy E. N., Chamberlain D. A. Amiodarone increases plasma digoxin concentrations. Br Med J (Clin Res Ed) 1981 Jan 24;282(6260):272–272. doi: 10.1136/bmj.282.6260.272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Nademanee K., Hendrickson J. A., Cannom D. S., Goldreyer B. N., Singh B. N. Control of refractory life-threatening ventricular tachyarrhythmias by amiodarone. Am Heart J. 1981 Jun;101(6):759–768. doi: 10.1016/0002-8703(81)90613-x. [DOI] [PubMed] [Google Scholar]
  23. Nademanee K., Singh B. N., Hendrickson J. A., Reed A. W., Melmed S., Hershman J. Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy. Circulation. 1982 Jul;66(1):202–211. doi: 10.1161/01.cir.66.1.202. [DOI] [PubMed] [Google Scholar]
  24. Polster P., Broekhuysen J. The adrenergic antagonism of amiodarone. Biochem Pharmacol. 1976 Jan 15;25(2):131–134. doi: 10.1016/0006-2952(76)90279-3. [DOI] [PubMed] [Google Scholar]
  25. Quyyumi A. A., Ormerod L. P., Clarke S. W., Evans T. R., Ward R. L. Pulmonary fibrosis--a serious side-effect of amiodarone therapy. Eur Heart J. 1983 Jul;4(7):521–524. doi: 10.1093/oxfordjournals.eurheartj.a061510. [DOI] [PubMed] [Google Scholar]
  26. Sclarovsky S., Lewin R. F., Kracoff O., Strasberg B., Arditti A., Agmon J. Amiodarone-induced polymorphous ventricular tachycardia. Am Heart J. 1983 Jan;105(1):6–12. doi: 10.1016/0002-8703(83)90270-3. [DOI] [PubMed] [Google Scholar]
  27. Sobol S. M., Rakita L. Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: a possible complication of a new antiarrhythmic drug. Circulation. 1982 Apr;65(4):819–824. doi: 10.1161/01.cir.65.4.819. [DOI] [PubMed] [Google Scholar]
  28. Tartini R., Kappenberger L., Steinbrunn W., Meyer U. A. Dangerous interaction between amiodarone and quinidine. Lancet. 1982 Jun 12;1(8285):1327–1329. doi: 10.1016/s0140-6736(82)92400-x. [DOI] [PubMed] [Google Scholar]
  29. Waxman H. L., Groh W. C., Marchlinski F. E., Buxton A. E., Sadowski L. M., Horowitz L. N., Josephson M. E., Kastor J. A. Amiodarone for control of sustained ventricular tachyarrhythmia: clinical and electrophysiologic effects in 51 patients. Am J Cardiol. 1982 Nov;50(5):1066–1074. doi: 10.1016/0002-9149(82)90419-2. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES